Loading company…
Regend Therapeutics is a Suzhou company developing regenerative medicine, including a lung cell therapy for COPD.
Established in 2015 and based in Suzhou, China, Regend Therapeutics (Suzhou Jimei Ruisheng Medical Technology Co., Ltd.) develops regenerative medicine products. Its main products include Regend001, an autologous lung precursor cell for chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and interstitial lung disease, along with Regend007 and Regend005. In February 2026, the company raised CNY 350 million in Series C funding from investors including Tibet Yuze Investment Management, Hefei High-tech Venture Capital and Tasly Capital Holdings Limited.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in